Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Valentino Conter

Showing results (11-20 of 131) with videos related to

Pageof 14
Sort By:
Expert Review of Hematology|November 5, 2014
Risk factors for relapse in childhood acute lymphoblastic leukemia: prediction and preventionFrancesco Ceppi, Giovanni Cazzaniga, Antonella Colombini, et al.
British Journal of Haematology|August 5, 2011
Defining the correct role of minimal residual disease tests in the management of acute lymphoblastic leukaemiaGiovanni Cazzaniga, Maria Grazia Valsecchi, Giuseppe Gaipa, et al.
Expert Review of Anticancer Therapy|September 21, 2011
Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual diseaseCarmelo Rizzari, Giovanni Cazzaniga, Tiziana Coliva, et al.
Haematologica|October 15, 2020
BCR-ABL1-like acute lymphoblastic leukemia in childhood and targeted therapyGunnar Cario, Veronica Leoni, Valentino Conter, et al.
Haematologica|January 26, 2006
Acute lymphoblastic leukemia in children with associated genetic conditions other than Down's syndrome. The AIEOP experienceOttavio Ziino, Roberto Rondelli, Concetta Micalizzi, et al.
Current Opinion in Oncology|February 6, 2013
Optimizing asparaginase therapy for acute lymphoblastic leukemiaCarmelo Rizzari, Valentino Conter, Jan Starý, et al.
Journal of Pediatric Gastroenterology and Nutrition|November 22, 2007
Alemtuzumab for giant cell hepatitis with autoimmune hemolytic anemiaAttilio Rovelli, Paola Corti, Chiara Beretta, et al.
Pediatric Blood & Cancer|April 24, 2014
Is multifocality a prognostic factor in childhood hepatoblastoma?Francesco Saettini, Valentino Conter, Massimo Provenzi, et al.
Pediatric Blood & Cancer|February 5, 2011
Fludarabine, cyclophosphamide, doxorubicin (FCD), and rituximab: a remission induction therapy for aggressive pediatric post-transplant lymphoproliferative disease (PTLD)Eugenia Giraldi, Massimo Provenzi, Roberto Fiocchi, et al.
Pediatric Blood & Cancer|August 9, 2005
ALK-positive plasmablastic B-cell lymphoma with the clathrin-ALK gene rearrangementGiuseppe Isimbaldi, Laura Bandiera, Emanuele S G d'Amore, et al.
Pageof 14

Showing results (11-20 of 131) with videos related to

Sort By:
Pageof 14
Expert Review of Hematology|November 5, 2014
Risk factors for relapse in childhood acute lymphoblastic leukemia: prediction and preventionFrancesco Ceppi, Giovanni Cazzaniga, Antonella Colombini, et al.
British Journal of Haematology|August 5, 2011
Defining the correct role of minimal residual disease tests in the management of acute lymphoblastic leukaemiaGiovanni Cazzaniga, Maria Grazia Valsecchi, Giuseppe Gaipa, et al.
Expert Review of Anticancer Therapy|September 21, 2011
Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual diseaseCarmelo Rizzari, Giovanni Cazzaniga, Tiziana Coliva, et al.
Haematologica|October 15, 2020
BCR-ABL1-like acute lymphoblastic leukemia in childhood and targeted therapyGunnar Cario, Veronica Leoni, Valentino Conter, et al.
Haematologica|January 26, 2006
Acute lymphoblastic leukemia in children with associated genetic conditions other than Down's syndrome. The AIEOP experienceOttavio Ziino, Roberto Rondelli, Concetta Micalizzi, et al.
Current Opinion in Oncology|February 6, 2013
Optimizing asparaginase therapy for acute lymphoblastic leukemiaCarmelo Rizzari, Valentino Conter, Jan Starý, et al.
Journal of Pediatric Gastroenterology and Nutrition|November 22, 2007
Alemtuzumab for giant cell hepatitis with autoimmune hemolytic anemiaAttilio Rovelli, Paola Corti, Chiara Beretta, et al.
Pediatric Blood & Cancer|April 24, 2014
Is multifocality a prognostic factor in childhood hepatoblastoma?Francesco Saettini, Valentino Conter, Massimo Provenzi, et al.
Pediatric Blood & Cancer|February 5, 2011
Fludarabine, cyclophosphamide, doxorubicin (FCD), and rituximab: a remission induction therapy for aggressive pediatric post-transplant lymphoproliferative disease (PTLD)Eugenia Giraldi, Massimo Provenzi, Roberto Fiocchi, et al.
Pediatric Blood & Cancer|August 9, 2005
ALK-positive plasmablastic B-cell lymphoma with the clathrin-ALK gene rearrangementGiuseppe Isimbaldi, Laura Bandiera, Emanuele S G d'Amore, et al.
Pageof 14